SCHEMBL7532457

SCHEMBL7532457

N=C1NC(CCC2CCCCC2)(c2ccccc2)C(=O)N1CC1CCC(C(=O)COc2ccccc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.39
BACE2 Q9Y5Z0 1/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 2/20 0.39
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
CHRM3 P20309 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
TRPA1 O75762 1/20 0.32
EDNRB P24530 1/20 0.32
EDNRA P25101 1/20 0.32
OPRD1 P41143 1/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
MMP2 P08253 1/20 0.31
MMP9 P14780 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8182231 0.87 ALDH1A1 (0.51) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL7524796 0.81 ALDH1A1 (0.46) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL7536559 0.76 KMT2A (0.42) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL7522625 0.74 ALDH1A1 (0.51) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL10120973 0.73 ALDH1A1 (0.41) BACE1ALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL7531185 0.72 PRMT5 (0.53) BACE1BACE2ALDH1A1PRMT5WDR77
SCHEMBL16640908 0.71 ALDH1A1 (0.35) BACE1BACE2ALDH1A1KMT2A
SCHEMBL7524362 0.70 POLB (0.38) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL7524123 0.70 ALDH1A1 (0.50) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL8267045 0.70 ALDH1A1 (0.34) ALDH1A1LMNASMN1; SMN2KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183252-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-22 US disclosed
US-8183252-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-22 US disclosed
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS CHRM1, CHRM2, PRSS1 BACE1 8/4885BACE2 30/4885ALDH1A1 4505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.